Sarah Walker

ASSISTANT PROFESSOR
Phone: (603) 862-3782
Office: Molecular, Cellular, & Biomedical Sciences, Rudman Hall Rm 185, Durham, NH 03824
Sarah Walker

My research focuses on understanding the roles of STATs and related transcription factors in breast and ovarian cancer and we use that knowledge to identify drugs to target the pathways associated with these transcription factors. In my lab, we use a 3D culturing system to mimic advanced stages of cancer. Moreover, we use a combination of wet lab experiments and bioinformatics to identify possible drugs for the treatment of breast and ovarian cancer.

Education

  • Ph.D., Cell and Developmental Biology, Harvard University
  • B.S., Biology, Rensselaer Polytechnic Institute
  • B.S., Bioinformatics and Molecular Biology, Rensselaer Polytechnic Institute

Research Interests

  • Breast Cancer
  • Cancer Biology
  • Cell Lines
  • Cellular Biology
  • Drug Discovery
  • Drug Resistance
  • Molecular Biology
  • Ovarian Cancer

Courses Taught

  • BENG 620: Tissue Engineering

Selected Publications

Liu, S., Marneth, A. E., Alexe, G., Walker, S. R., Gandler, H. I., Ye, D. Q., . . . Frank, D. A. (2018). The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Advances, 2(23), 3428-3442. doi:10.1182/bloodadvances.2018016733

Karakasheva, T. A., Lin, E. W., Tang, Q., Qiao, E., Waldron, T. J., Soni, M., . . . Rustgi, A. K. (2018). IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Research, 78(17), 4957-4970. doi:10.1158/0008-5472.can-17-2268

Egusquiaguirre, S. P., Yeh, J. E., Walker, S. R., Liu, S., & Frank, D. A. (2018). The STAT3 Target Gene TNFRSF1A Modulates the NF-κB Pathway in Breast Cancer Cells. Neoplasia, 20(5), 489-498. doi:10.1016/j.neo.2018.03.004

Yuzugullu, H., Von, T., Thorpe, L. M., Walker, S. R., Roberts, T. M., Frank, D. A., & Zhao, J. J. (2016). NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways. Cell Discovery, 2(1). doi:10.1038/celldisc.2016.30

Xiang, M., Kim, H., Ho, V. T., Walker, S. R., Bar-Natan, M., Anahtar, M., . . . Frank, D. A. (2016). Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood, 128(14), 1845-1853. doi:10.1182/blood-2015-07-660506

Chmielecki, J., Crago, A. M., Rosenberg, M., O'Connor, R., Walker, S. R., Ambrogio, L., . . . Meyerson, M. (2013). Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nature Genetics, 45(2), 131-132. doi:10.1038/ng.2522

Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., . . . Polyak, K. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors. Journal of Clinical Investigation, 121(7), 2723-2735. doi:10.1172/jci44745

Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., . . . Frank, D. A. (2011). The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood, 117(12), 3421-3429. doi:10.1182/blood-2009-11-255232

Walker, S. R., Nelson, E. A., Zou, L., Chaudhury, M., Signoretti, S., Richardson, A., & Frank, D. A. (2009). Reciprocal Effects of STAT5 and STAT3 in Breast Cancer. Molecular Cancer Research, 7(6), 966-976. doi:10.1158/1541-7786.mcr-08-0238

Keese, C. R., Wegener, J., Walker, S. R., & Giaever, I. (2004). Electrical wound-healing assay for cells in vitro. Proceedings of the National Academy of Sciences, 101(6), 1554-1559. doi:10.1073/pnas.0307588100

Most Cited Publications